Table 2.

Prevalence of 15 most common HPV genotypes in HPV-positive LSILs and comparison with that in SCC

HPV genotypeHPV-positive LSIL*
SCC,
SCC/LSIL
Tested, nHPV positive, %Tested, nHPV positive, %Prevalence ratio (95% CI)
HPV165,91026.68,59454.32.06 (2.02-2.11)
HPV185,9108.68,50212.61.47 (1.39-1.54)
HPV453,5454.95,1744.20.85 (0.77-0.94)
HPV335,7447.68,4494.30.58 (0.54-0.62)
HPV315,80111.77,2044.20.36 (0.34-0.39)
HPV583,3808.55,6463.00.36 (0.32-0.39)
HPV523,2628.85,3042.50.28 (0.25-0.31)
HPV354,7545.96,2231.00.17 (0.15-0.20)
HPV593,2326.04,4880.80.13 (0.11-0.16)
HPV63,6388.16,5690.60.08 (0.06-0.09)
HPV563,3489.74,4930.70.07 (0.06-0.09)
HPV513,56610.94,5800.60.06 (0.05-0.07)
HPV393,2517.83,8990.40.05 (0.04-0.07)
HPV663,1328.54,7990.20.02 (0.02-0.04)
HPV532,51610.13,0530.10.01 (0.01-0.02)
  • * Regional distribution of included cases: Europe 46.5%, North America 32.9%, South/Central America 14.8%, Africa 3.0%, and Asia 2.9%.

  • Data from Clifford et al. (32).

  • Regional distribution of included cases: Europe 32.0%, North America 13.0%, South/Central America 16.5%, Africa 6.9%, and Asia 31.7%.